{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:24:22Z","timestamp":1762507462476,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00192-018-3721-4","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T03:32:53Z","timestamp":1533267173000},"page":"701-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-6014","authenticated-orcid":false,"given":"Justin","family":"Houman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Moradzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Asanad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer T.","family":"Anger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyn S.","family":"Eilber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"issue":"11","key":"3721_CR1","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on QoL, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"unstructured":"Abrams P, Birder KEAL, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W. Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence International Continence Society, 2009.","key":"3721_CR2"},{"issue":"6A Suppl","key":"3721_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0090-4295(97)00583-9","volume":"50","author":"W Artibani","year":"1997","unstructured":"Artibani W. Diagnosis and significance of idiopathic overactive bladder. Urology. 1997;50(6A Suppl):25\u201332. discussion 33-5","journal-title":"Urology"},{"issue":"5","key":"3721_CR4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley EA, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol. 2015;193(5):1572\u201380.","journal-title":"J Urol"},{"issue":"11","key":"3721_CR5","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.clinthera.2013.08.017","volume":"35","author":"MB Chancellor","year":"2013","unstructured":"Chancellor MB, et al. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013;35(11):1744\u201351.","journal-title":"Clin Ther"},{"issue":"6","key":"3721_CR6","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416\u201322.","journal-title":"J Urol"},{"issue":"2","key":"3721_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and QoL in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249\u201356.","journal-title":"Eur Urol"},{"issue":"5","key":"3721_CR8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.ajog.2004.11.052","volume":"192","author":"M Werner","year":"2005","unstructured":"Werner M, Schmid DM, Schussler B. Efficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol. 2005;192(5):1735\u201340.","journal-title":"Am J Obstet Gynecol"},{"unstructured":"Weckx F, et al. The role of botulinum toxin a in treating neurogenic bladder. Transl Androl Urol. 2016;5(1):63\u201371.","key":"3721_CR9"},{"doi-asserted-by":"crossref","unstructured":"Houman J, Anger JJJ, Eilber K. What is the ideal antibiotic prophylaxis for intravesical Botox injection? A comparison of two different regimens. American Urological Association Annual Meeting 2017. 2017.","key":"3721_CR10","DOI":"10.1016\/j.juro.2017.02.2418"},{"issue":"1","key":"3721_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100\u201319.","journal-title":"Eur Urol"},{"issue":"3","key":"3721_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","volume":"81","author":"M Kennelly","year":"2013","unstructured":"Kennelly M, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(3):491\u20137.","journal-title":"Urology"},{"doi-asserted-by":"crossref","unstructured":"Schurch B, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196\u2013200.","key":"3721_CR13","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"issue":"1","key":"3721_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/nau.22892","volume":"36","author":"YH Jiang","year":"2017","unstructured":"Jiang YH, Ong HL, Kuo HC. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-a real-life practice of 290 cases in a single center. Neurourol Urodyn. 2017;36(1):142\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"3721_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1756287216672180","volume":"9","author":"D Eldred-Evans","year":"2017","unstructured":"Eldred-Evans D, Sahai A. Medium- to long-term outcomes of botulinum toxin a for idiopathic overactive bladder. Ther Adv Urol. 2017;9(1):3\u201310.","journal-title":"Ther Adv Urol"},{"key":"3721_CR16","first-page":"CD006576","volume":"5","author":"EL Zani","year":"2011","unstructured":"Zani EL, Clark OA, Rodrigues Netto N, Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev. 2011;5:CD006576.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-018-3721-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-018-3721-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-018-3721-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T17:20:32Z","timestamp":1566840032000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-018-3721-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3721"],"URL":"https:\/\/doi.org\/10.1007\/s00192-018-3721-4","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"17 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no financial disclosures or conflicts of interest to report.All authors made significant contributions to the final manuscript, and all authors have approved the final submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}